UX-DA001 / Shanghai Yuesai Biotech - LARVOL DELTA

UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson's disease, in its Phase 1 study (The Manila Times) - "Shanghai UniXell Biotechnology Co., Ltd...announced the successful first administration of its proprietary Parkinson's disease cell drug UX-DA001 in China in March 2025. The Phase I clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of UX-DA001 in patients with Parkinson's disease."

Trial status • Parkinson's Disease